Page 49 - Read Online

dependent on APOE genotype and duration of disease. neurotransmitter abnormalities. Neurobiol Dis 2005;18:602‑17.
J Neuropathol Exp Neurol 1994;53:429‑37. 27. El‑Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin:
8. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, an enzyme candidate to slow the progression of Alzheimer’s disease.
Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy‑Lahad E, Am J Pathol 2008;172:1342‑54.
Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, 28. Hook G, Hook V, Kindy M. The cysteine protease inhibitor,
Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta‑protein E64d, reduces brain amyloid‑β and improves memory deficits in
similar to that in the senile plaques of Alzheimer’s disease is increased Alzheimer’s disease animal models by inhibiting cathepsin B, but
in vivo by the presenilin 1 and 2 and APP mutations linked to familial not BACE1, β‑secretase activity. J Alzheimers Dis 2011;26:387‑408.
Alzheimer’s disease. Nat Med 1996;2:864‑70. 29. Hook V, Kindy M, Hook G. Cysteine protease inhibitors effectively
9. Hardy J. The Alzheimer family of diseases: many etiologies, one reduce in vivo levels of brain beta‑amyloid related to Alzheimer’s
pathogenesis? Proc Natl Acad Sci U S A 1997;94:2095‑7. disease. Biol Chem 2007;388:247‑52.
10. Selkoe DJ. The cell biology of beta‑amyloid precursor protein and 30. Hook G, Hook VY, Kindy M. Cysteine protease inhibitors reduce brain
presenilin in Alzheimer’s disease. Trends Cell Biol 1998;8:447‑53. beta‑amyloid and beta‑secretase activity in vivo and are potential
11. St. George‑Hyslop PH. The molecular genetics of Alzheimer disease. Alzheimer’s disease therapeutics. Biol Chem 2007;388:979‑83.
In: Terry RD, Katzman R, Bick KL, editors. Alzheimer Disease. 31. Hook VY, Kindy M, Hook G. Inhibitors of cathepsin B improve
New York: Raven Press; 1994. p. 345‑52. memory and reduce beta‑amyloid in transgenic Alzheimer disease
12. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, mice expressing the wild‑type, but not the Swedish mutant,
Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, beta‑secretase site of the amyloid precursor protein. J Biol Chem
Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, 2008;283:7745‑53.
Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, 32. Hook VY, Kindy M, Reinheckel T, Peters C, Hook G. Genetic
Da Silva HA, Haines JL, Perkicak‑Vance MA, Tanzi RE, Roses AD, cathepsin B deficiency reduces beta‑amyloid in transgenic mice
Fraser PE, Rommens JM, St George‑Hyslop PH. Cloning of a gene expressing human wild‑type amyloid precursor protein. Biochem
bearing missense mutations in early‑onset familial Alzheimer’s Biophys Res Commun 2009;386:284‑8.
disease. Nature 1995;375:754‑60. 33. Kindy MS, Yu J, Zhu H, El‑Amouri SS, Hook V, Hook GR. Deletion
13. Levy‑Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, of the cathepsin B gene improves memory deficits in a transgenic
Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K. Candidate ALZHeimer’s disease mouse model expressing AßPP containing the
gene for the chromosome 1 familial Alzheimer’s disease locus. wild‑type ß‑secretase site sequence. J Alzheimers Dis 2012;29:827‑40.
Science 1995;269:973‑7. 34. Lassiter TL, Barone S Jr, Moser VC, Padilla S. Gestational exposure
14. Wisniewski T, Frangione B. Apolipoprotein E: a pathological to chlorpyrifos: dose response profiles for cholinesterase and
chaperone protein in patients with cerebral and systemic amyloid. carboxylesterase activity. Toxicol Sci 1999;52:92‑100.
Neurosci Lett 1992;135:235‑8. 35. Marty MS, Andrus AK, Bell MP, Passage JK, Perala AW, Brzak KA,
15. de la Fuente‑Fernández R, Calne DB. Evidence for environmental Bartels MJ, Beck MJ, Juberg DR. Cholinesterase inhibition and
causation of Parkinson’s disease. Parkinsonism Relat Disord toxicokinetics in immature and adult rats after acute or repeated
2002;8:235‑41. exposures to chlorpyrifos or chlorpyrifos‑oxon. Regul Toxicol
16. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Pharmacol 2012;63:209‑24.
Cory‑Slechta DA. Potentiated and preferential effects of combined 36. de Magalhães JP, Wuttke D, Wood SH, Plank M, Vora C.
paraquat and maneb on nigrostriatal dopamine systems: Genome‑environment interactions that modulate aging: powerful
environmental risk factors for Parkinson’s disease? Brain Res targets for drug discovery. Pharmacol Rev 2012;64:88‑101.
2000;873:225‑34. 37. Rondeau V, Commenges D, Jacqmin‑Gadda H, Dartigues JF.
17. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory‑Slechta DA. Relation between aluminum concentrations in drinking water and
The nigrostriatal dopaminergic system as a preferential target of Alzheimer’s disease: an 8‑year follow‑up study. Am J Epidemiol
repeated exposures to combined paraquat and maneb: implications 2000;152:59‑66.
for Parkinson’s disease. J Neurosci 2000;20:9207‑14. 38. Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors
18. Barker DJ. The fetal and infant origins of disease. Eur J Clin Invest for Alzheimer’s disease: a population‑based, longitudinal study in
1995;25:457‑63. Manitoba, Canada. Int J Epidemiol 2001;30:590‑7.
19. Osmond C, Barker DJ. Fetal, infant, and childhood growth 39. Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB,
are predictors of coronary heart disease, diabetes, and McDowell I. Risk factors for Alzheimer’s disease: a prospective
hypertension in adult men and women. Environ Health Perspect analysis from the Canadian Study of Health and Aging. Am J
2000;108 Suppl 3:545‑53. Epidemiol 2002;156:445‑53.
20. Bilbo SD, Schwarz JM. Early‑life programming of later‑life brain 40. Baldi I, Lebailly P, Mohammed‑Brahim B, Letenneur L, Dartigues JF,
and behavior: a critical role for the immune system. Front Behav Brochard P. Neurodegenerative diseases and exposure to pesticides
Neurosci 2009;3:14. in the elderly. Am J Epidemiol 2003;157:409‑14.
21. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, 41. Kamel F, Hoppin JA. Association of pesticide exposure with
Droller D. Early environmental origins of neurodegenerative disease neurologic dysfunction and disease. Environ Health Perspect
in later life. Environ Health Perspect 2005;113:1230‑3. 2004;112:950‑8.
22. Barker DJ, Lackland DT. Prenatal influences on stroke mortality in 42. Kumar V, Kinsella LJ. Healthy brain aging:effect of head injury,
England and Wales. Stroke 2003;34:1598‑602. alcohol and environmental toxins. Clin Geriatr Med 2010:26:29‑44.
23. Lackland DT. Mechanisms and fetal origins of kidney disease. J Am 43. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace
Soc Nephrol 2005;16:2531‑2. elements related to oxidative damage in Alzheimer’s disease brain.
24. Lahiri DK, Maloney B. The “LEARn” (latent early‑life associated Neurotoxicology 1998;19:339‑45.
regulation) model: an epigenetic pathway linking metabolic and 44. Zawia NH, Basha MR. Environmental risk factors and the
cognitive disorders. J Alzheimers Dis 2012;30 Suppl 2:S15‑30. developmental basis for Alzheimer’s disease. Rev Neurosci
25. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic 2005;16:325‑37.
explanation for idiopathic neurobiological diseases. Mol Psychiatry 45. Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, Tanzi RE,
2009;14:992‑1003. Rogers JT, Huang X. Metal exposure and Alzheimer’s pathogenesis.
26. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, J Struct Biol 2006;155:45‑51.
Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR. 46. Platt B. Experimental approaches to assess metallotoxicity
Episodic‑like memory deficits in the APPswe/PS1dE9 mouse model and ageing in models of Alzheimer’s disease. J Alzheimers Dis
of Alzheimer’s disease: relationships to beta‑amyloid deposition and 2006;10:203‑13.

Neuroimmunol Neuroinflammation | Volume 2 | Issue 1 | January 15, 2015 41